Press Room

Webinar: Evaluating the Best Formulations for Amorphous Solid Dispersions by Spray Drying

Start
Tuesday, February 28, 2023 - 16:00
End
Tuesday, February 28, 2023 - 17:28
Location: online
Webinar session 1 Spray Drying_Feb28 - SEM image of a particle in a dark green background

This is the first session of a three-part webinar series on Amorphous Solid Dispersions by Spray Drying: From Early Formulation to Commercial Lifecycle Management.

 

Watch On-demand.

Gated content. Registration is required.

 

 

Learn more about this webinar series here.

 

Featured Hovione experts in this webinar
Webinar Series Spray Drying Speakers - Alexandre Ribeiro | Hovione
Webinar Series Spray Drying Speakers - Ines Ramos | Hovione
Webinar Series Spray Drying Speakers - Pedro Monteiro | Hovione
Alexandre Ribeiro, Ph.D.

Senior Analytical Scientist 

R&D, Analytical Development
Inês Ramos, Ph.D.

Scientist 

R&D Oral Drug Product - Formulation Group
Pedro Monteiro, M.Sc. 

Scientist 

R&D Oral Drug Product - Formulation Group​​​​

 

Alexandre Ribeiro, Inês Ramos, and Pedro Monteiro kick-off the series by focusing on the role of amorphous solid dispersions in modern oral drugs and how the right formulation for a drug candidate can be selected using Hovione’s proprietary screening methodology. This method is performed via an automated high-throughput system that was developed over many years of experience with formulation of ASDs. The speakers will provide an understanding of the methodology, the evaluation process, and the studies typically utilized, as well as key information needed to make a formal assessment of the best candidates.

 

Your Key Learning Objectives

  • Understand the increasing importance of amorphous solid dispersions in oral drug delivery of new chemical entities
  • Get an overview of Hovione’s methodology to screen the best formulations in amorphous solid dispersions for a given API candidate
  • Learn about the formulation criteria based on stability, performance, and manufacturability data

 

Who Should Attend 

This webinar is suitable for anyone working in formulation of oral drugs, procurement, and outsourcing teams or as a project manager, who is interested in understanding the whole assessment process and their role in it.

 

 

 

Watch On-demand.

Gated content. Registration is required.

 

 

Do you have a challenging project needing differentiating technologies and an innovative approach?

Get in touch today

 

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026